Microchip Biotechnologies Inc.
This article was originally published in Start Up
Executive Summary
Even as next-generation sequencing technologies make their way to the market, improving the efficiency of sample prep at the front end of large-scale genome sequencing will continue to be a viable strategy for significantly driving down costs and in so doing, expand applications. That's the initial strategy of Microchip Biotechnologies, which is commercializing microfluidic technology originally developed in the lab of Richard Mathies at Berkeley.